Navigation Links
Amgen Statement on CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
Date:3/18/2011

offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this statement related to our product candidates is preliminary and investigative and is not part of the labeling approved by the U.S. FDA or the European Medicines Agency (EMA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA, EMA or other applicable regulatory bodies can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the approved labeling for the products, and not the information discussed in this statement. CONTACT: Amgen Carrie Deverell: +41 41 3690 308 (E.U. media) Christine Regan: +1 (805) 447-5476 (U.S. media) Arvind Sood: +1 (805)-447-1060 (investors)(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

(i) Douillard, JE et al. Randomized, Phase 3 Study (PRIME) of Panitumumab with FOLFOX4 versus FOLFOX4 Alone as First-Line Treatment in Patients With Previously Untreated Metastatic Col
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference
2. Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results
3. Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
4. Amgen and Xencor Enter Option Deal to Co-Develop Xencors Novel Antibody for Autoimmune Diseases
5. Call for Applications: The Amgen Award for Science Teaching Excellence
6. Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits
7. Amgen to Provide Testimony at FDA Hearing on Biosimilars
8. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
9. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
10. Array BioPharma and Amgen Partner in Type 2 Diabetes
11. Amgen to Present at Lazard Capital Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... dental biomaterial market will grow moderately through 2023 as ... and growing awareness of dental biomaterials all spur procedure ... such as China and ... bring dental procedures within reach for a larger proportion ...
(Date:12/17/2014)... The Activated Carbon Manufacturing industry ... IBISWorld updated its original industry research report. , ... intensified focus on environmental policy. Over the five years ... power plants and a range of other industrial facilities ... Sarah Kahn, “a range of downstream industrial sectors rely ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... ... its Scientific Advisory Board , ... Westlake Village, Calif. (PRWEB) October 9, 2009 -- Nanogea, a nano-biotech company focused on commercializing ... C. Thomas Caskey and Dr. Saul Tendler have joined its scientific advisory board. , ...
... 8 CardioDx, a cardiovascular genomic diagnostics company, announced ... as Chairman of the company,s Board of Directors. CardioDx ... expression test to quantify the likelihood of obstructive(1) coronary ... , "Dr. Lange brings an ideal perspective to ...
... ... completely noninvasive, biometric health evaluation system designed for ordinary people who want to proactively monitor ... ... is the first of its kind, fully automated, and completely noninvasive, biometric health evaluation system ...
Cached Biology Technology:Nanogea Announces New Scientific Advisory Board Members 2Nanogea Announces New Scientific Advisory Board Members 3CardioDx Announces Appointment of Dr. Louis G. Lange as Chairman of the Board of Directors 2CardioDx Announces Appointment of Dr. Louis G. Lange as Chairman of the Board of Directors 3IridoTech Announces IridoLab Self Service Kiosk 2
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... cases, scientists at Johns Hopkins have discovered the genetic origins ... the leading reason for corneal transplantation in the United States. ... the cells covering the clear, outermost lens of the eye ... Late in life, the dystrophy causes swelling of the cornea ...
... by the sleek and efficient propulsion of squid, jellyfish ... researcher has designed a new generation of compact vortex ... maneuver and dock underwater vehicles at low speeds and ... seemingly inspired by the plots of two classic sci-fi ...
... pregnant woman will give birth to a child with Down Syndrome ... Although it is a fact that as women get older, they ... factors also play a role. According to Markus Neuhäuser and ... at University Hospital Essen, in Germany, the risk of a child ...
Cached Biology News:Leading reason for corneal transplants comes into focus 2Leading reason for corneal transplants comes into focus 3Squid-inspired design could mean better handling of underwater vehicles 2Down syndrome: It's not just the age factor 2
Request Info...
Multidrop Micro high speed 1 l bulk reagent dispenser rapidly, precisely and accurately dispenses microvolumes of 1-50 l into 384- and 96-well microplates....
...
...
Biology Products: